Swiss National Bank Has $1.57 Million Stake in Eagle Pharmaceuticals Inc (NASDAQ:EGRX)

Swiss National Bank increased its holdings in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 45.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,700 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,500 shares during the quarter. Swiss National Bank owned 0.14% of Eagle Pharmaceuticals worth $1,566,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Meeder Asset Management Inc. raised its position in Eagle Pharmaceuticals by 232.6% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,866 shares of the specialty pharmaceutical company’s stock worth $141,000 after purchasing an additional 1,305 shares during the period. Citigroup Inc. raised its position in Eagle Pharmaceuticals by 4.0% in the 1st quarter. Citigroup Inc. now owns 46,833 shares of the specialty pharmaceutical company’s stock worth $2,468,000 after purchasing an additional 1,806 shares during the period. US Bancorp DE raised its position in Eagle Pharmaceuticals by 191.9% in the 2nd quarter. US Bancorp DE now owns 2,767 shares of the specialty pharmaceutical company’s stock worth $209,000 after purchasing an additional 1,819 shares during the period. Piedmont Investment Advisors LLC purchased a new position in Eagle Pharmaceuticals in the 2nd quarter worth $150,000. Finally, New York State Common Retirement Fund raised its position in Eagle Pharmaceuticals by 3.6% in the 1st quarter. New York State Common Retirement Fund now owns 64,467 shares of the specialty pharmaceutical company’s stock worth $3,397,000 after purchasing an additional 2,234 shares during the period.

A number of brokerages recently commented on EGRX. ValuEngine upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 10th. BidaskClub upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, September 29th. Zacks Investment Research upgraded shares of Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, June 13th. TheStreet upgraded shares of Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Thursday, August 9th. Finally, boosted their price objective on shares of Eagle Pharmaceuticals to $119.00 and gave the company a “buy” rating in a research report on Tuesday, July 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $86.50.

Shares of EGRX opened at $63.43 on Tuesday. The stock has a market cap of $1.04 billion, a PE ratio of 18.82 and a beta of 1.32. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.09 and a current ratio of 4.22. Eagle Pharmaceuticals Inc has a 1-year low of $48.84 and a 1-year high of $85.66.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.80 by $0.15. The firm had revenue of $59.30 million for the quarter, compared to analyst estimates of $51.78 million. Eagle Pharmaceuticals had a net margin of 13.81% and a return on equity of 19.71%. Research analysts expect that Eagle Pharmaceuticals Inc will post 2.15 EPS for the current year.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Featured Story: The Discount Rate – What You Need to Know

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply